Morus alba Linn. leaf as a food and drug homologs: chemical composition and structure, biological activity, mechanism of action, research progress on its biosynthetic pathway, and application challenges in future food

Read full text
Authors: Yanhui Yi, Hengyu Lv, Yangping Wang, Feng Zhao, Jianzeng Xin, Sheng Liu
Cited by: 3
References: 110

Abstract

Mulberry ( Morus alba L.) leaf, recognized as a traditional Chinese medicine, plays an important role in both food and pharmaceutical applications owing to its distinctive medicinal-food homology properties. This article systematically reviews the chemical structure characteristics, pharmacological activities, and related mechanisms of action of the main active ingredients in mulberry leaves, including flavonoids, alkaloids, and phenolic acids. The focus is on the biosynthetic pathways of flavonoids and alkaloids, and explores the feasibility of large-scale production through synthetic biology strategies and the use of key enzymes and synthetic intermediates. It also analyzes the main challenges faced by mulberry leaves in pharmaceutical and food applications, such as poor solubility and unpleasant odors, and proposes targeted solutions. By integrating existing research results, this article aims to systematically elucidate the medicinal and nutritional functions of mulberry leaves, providing a theoretical basis and practical guidance for their in-depth development and rational utilization in the health industry. • This review delves into the multifaceted value of mulberry leaf. • Chemical structure and biological activities of mulberry leaf were summarized. • It highlights its traditional uses in medicine and nutrition. • We explore innovative strategies for mulberry leaf utilization in functional foods.

Fields of Study & Subjects

Bioactive natural compounds Ziziphus Jujuba Studies and Applications Plant Gene Expression Analysis

Publication details

Journal / source
Journal of Agriculture and Food Research
Publisher
Elsevier BV
Volume
27
Pages
102814–102814
Publication date
4 March 2026
Language
EN